Reviewer's report

**Title:** Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

**Version:** 1  **Date:** 12 May 2013

**Reviewer:** Jose Ceron

**Reviewer's report:**

The question posed by the authors is interesting and well defined in the introduction and the problem is well documented.

Results are well defined and related. Authors describe the differences between both groups, as age, dissected lymph nodes, tumor size, and performance status. These data seem to assign a better prognosis to the treatment group, and this could affect the results.

Discussion is well done and structured. Limitations of the study are well defined.

In conclusion, this is an interesting retrospective study on a very interesting aspect of early lung cancer and results seem good. However, some important changes must be done before its publication.

**Major Compulsory Revisions**

1. In the patients and methods section are included some results (“…60 (50.4%) underwent platinum-based adjuvant...”).

2. Seventh edition of the TNM classification was published in 2007, so most of the patients included in the study (from 2000 to 2007) were classified as T2 according to prior classification, and reclassified to T2a for this study. Authors should explain this point at methods.

3. Comorbidities should be defined as diagnostic criteria, not as arritmia, hypertension...

4. Authors don’t describe the indications or selection criteria for the adjuvant treatment group. Preferences of the surgeon and physician are not acceptable as criterion for treatment. This point is a serious methodological problem due to its difficult to replicate results.

5. Authors should describe if any morbidity or mortality related with chemotherapy was present.

**Discretionary Revisions**

1. It would be very interesting to know cancer related survival or cancer related deaths. How many cases died due to causes not related to NSCLC?

2. In the patterns of recurrence, to know the rates of local, regional and distant recurrence by treatment or observation group will be very interesting.
Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no conflict of interests or financial competing interests with any institution or organization related with this manuscript.